This podcast was initiated and funded by Bayer Australia Ltd. Treatment options for men with non-metastatic castrate-resistant prostate cancer (nmCRPC) now extend beyond continued androgen deprivation therapy to include the second-generation androgen-receptor inhibitors. In this podcast the limbic speaks to Doctor Neal Shore from the Carolina Urologic Research Centre in the United States and local ...
Podcast: How second-generation androgen-receptor inhibitors have altered the treatment of nmCRPC
5 Apr 2021
Sponsored by Bayer Australia Limited